Status: Recruiting
Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease
The goal of this clinical trial is to test if the drug SKY-0515, an oral medication, can lower harmful proteins linked to Huntington's Disease (HD) and improve the symptoms of participants with HD. This study includes men and women aged 25 and older who have HD confirmed by genetic testing and meet certain requirements for physical ability and independence.
Participants needed: 400
Trial details
Phase: Phase 2, Phase 3Age: 25+Biological sex: AllType: InterventionalSponsor: Skyhawk Therapeutics, Inc.Updated: Jul 13, 2026Locations: 19
Eligibility criteria
25 years or older. [+7]
Other Serious health problems or brain/spinal issues that could interfere with t... [+10]